Poly Medicure Limited (POLYMED.NS)
New Delhi, IN
Poly Medicure Limited (PML) specializes in the production and distribution of a wide array of medical devices. Its extensive product portfolio encompasses a comprehensive range of infusion equipment, including IV cannulas, midline and arterial catheters, three-way stopcocks, various infusion sets (standard, safety winged, and measured volume), manifolds, extension lines, stylets/mandrins with luer locks, vial access spikes, central venous catheters, CVP manometers, needle-free connectors, pre-filled syringes, vascular access devices, and blood administration sets. The company also supplies diverse feeding solutions, such as nasogastric, infant, and gastro-duodenal feeding tubes, alongside umbilical catheters. Urology offerings include urine collection bags (with or without measured volume meters), Foley balloon catheters, irrigation sets, and general urine drainage catheters. For respiratory and anesthesia care, PML manufactures endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator and Bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. The company also provides oncology-specific products. Oxygen and respiratory therapy devices feature endobronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oropharyngeal airways, and various oxygen masks, including variable concentration, reservoir, fixed concentration, and aerosol therapy types. Its renal care segment comprises dialyzers, blood lines, complete dialysis systems, fistula needles, hemodialysis catheters, and peritoneal dialysis and transfusion sets. Surgical drainage products include closed wound suction units, underwater seal drainage systems, high-pressure vacuum bottles, Yankauer suction sets, and thoracic drainage catheters. For phlebotomy and blood diagnostics, PML supplies blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors. Blood bag systems are also available. Personal protective equipment (PPE) such as face shields and polymasks, along with viral transport medium kits, form part of its offering. Further miscellaneous medical disposables encompass insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. Established in 1995, the company is headquartered in New Delhi, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.94% | -1.72% | +1.81% | +14.39% | -24.20% | -18.83% | -40.87% | +47.64% | +42.28% | +725.10% | +4,228.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+12.3% ★ Q1'26: +21.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-6.9% Q1'26: -26.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+2.8% Q1'26: -12.3% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+17.4% ★ Q1'26: +13.5% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+9.3% ★ Q1'26: +8.4% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+2.2% Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.80× ★ Q1'26: 0.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2013 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 6 EPS Ana. |
Mar 2027 6 Rev. Ana. 5 EPS Ana. |
Mar 2028 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.60B
est: 2.49B (+4.5%)
|
3.90B
est: 3.76B (+3.9%)
|
4.12B
est: 3.90B (+5.7%)
|
4.55B
est: 4.50B (+1.0%)
|
5.20B
est: 5.01B (+3.8%)
|
6.11B
est: 5.93B (+2.9%)
|
6.87B
est: 6.72B (+2.3%)
|
7.86B
est: 7.87B (-0.1%)
|
9.23B
est: 9.12B (+1.2%)
|
11.15B
est: 11.11B (+0.3%)
|
13.76B
est: 13.64B (+0.9%)
|
16.70B
est: 16.90B (-1.2%)
|
18.92B
18.39B – 19.34B
+12.0% YoY
|
22.42B
21.32B – 23.59B
+18.5% YoY
|
26.70B
24.84B – 29.33B
+19.1% YoY
|
| EBITDA |
689.87M
est: 631.63M (+9.2%)
|
841.59M
est: 954.58M (-11.8%)
|
857.76M
est: 976.56M (-12.2%)
|
922.01M
est: 1.13B (-18.3%)
|
1.20B
est: 1.26B (-4.8%)
|
1.30B
est: 1.48B (-12.2%)
|
1.63B
est: 1.64B (-0.9%)
|
2.13B
est: 1.97B (+7.8%)
|
2.12B
est: 1.96B (+8.2%)
|
2.68B
est: 2.78B (-3.8%)
|
3.58B
est: 3.47B (+3.2%)
|
4.52B
est: 4.29B (+5.3%)
|
4.81B
4.67B – 4.92B
+12.0% YoY
|
5.70B
5.42B – 5.99B
+18.5% YoY
|
6.79B
6.31B – 7.45B
+19.1% YoY
|
| EBIT |
562.89M
est: 504.00M (+11.7%)
|
653.52M
est: 761.70M (-14.2%)
|
647.47M
est: 779.24M (-16.9%)
|
690.91M
est: 900.07M (-23.2%)
|
911.62M
est: 854.53M (+6.7%)
|
936.95M
est: 1.19B (-21.0%)
|
1.24B
est: 1.34B (-7.7%)
|
1.67B
est: 1.57B (+6.1%)
|
1.60B
est: 1.61B (-0.9%)
|
2.13B
est: 1.99B (+7.1%)
|
2.96B
est: 2.77B (+7.1%)
|
3.72B
est: 3.43B (+8.5%)
|
3.84B
3.73B – 3.92B
+12.0% YoY
|
4.54B
4.32B – 4.78B
+18.5% YoY
|
5.41B
5.04B – 5.95B
+19.1% YoY
|
| Net Income |
242.30M
est: 193.60M (+25.2%)
|
623.23M
est: 689.75M (-9.6%)
|
482.68M
est: 686.43M (-29.7%)
|
551.25M
est: 314.49M (+75.3%)
|
705.94M
est: 701.03M (+0.7%)
|
653.99M
est: 712.72M (-8.2%)
|
958.78M
est: 1.06B (-9.2%)
|
1.36B
est: 1.46B (-7.0%)
|
1.47B
est: 1.25B (+17.2%)
|
1.79B
est: 1.91B (-6.1%)
|
2.58B
est: 2.64B (-2.2%)
|
3.39B
est: 3.28B (+3.1%)
|
3.43B
3.22B – 3.55B
+4.4% YoY
|
3.93B
3.58B – 4.07B
+14.5% YoY
|
4.83B
4.23B – 5.29B
+23.0% YoY
|
| SGA |
589.92M
est: 457.48M (+28.9%)
|
686.62M
est: 691.40M (-0.7%)
|
791.25M
est: 707.32M (+11.9%)
|
930.87M
est: 817.00M (+13.9%)
|
1.04B
est: 909.31M (+13.9%)
|
1.22B
est: 1.08B (+13.8%)
|
1.43B
est: 1.22B (+17.4%)
|
1.45B
est: 1.43B (+1.4%)
|
1.67B
est: 2.86B (-41.6%)
|
2.08B
est: 3.31B (-37.3%)
|
2.52B
est: 2.51B (+0.2%)
|
3.11B
est: 3.11B (-0.1%)
|
3.48B
3.38B – 3.56B
+12.0% YoY
|
4.13B
3.92B – 4.34B
+18.5% YoY
|
4.91B
4.57B – 5.40B
+19.1% YoY
|
| EPS |
2.75
est: 1.95 (+41.0%)
|
7.07
est: 6.95 (+1.7%)
|
5.47
est: 7.05 (-22.4%)
|
6.25
est: 3.23 (+93.5%)
|
8.00
est: 7.20 (+11.1%)
|
7.41
est: 7.32 (+1.2%)
|
10.86
est: 10.84 (+0.2%)
|
15.25
est: 15.00 (+1.7%)
|
15.28
est: 14.65 (+4.3%)
|
18.69
est: 19.60 (-4.6%)
|
26.92
est: 26.60 (+1.2%)
|
34.13
est: 33.10 (+3.1%)
|
34.56
32.40 – 35.74
+4.4% YoY
|
39.56
36.10 – 41.00
+14.5% YoY
|
48.66
42.60 – 53.30
+23.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.75M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 129.1K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 57.2K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 6.37M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 86.0K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 6.78M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 401.0K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 10.2K | 0.22% |
| 9 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 5.4K | 0.24% |
| 10 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 5.4K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Himanshu Baid | Chief Executive Officer, MD & Director | 214M | male |
| Rishi Baid | Joint MD & Executive Director | 209M | male |
| Vishal Baid | Executive Director & Senior Vice President of Corporate Sales & Marketing | 20M | male |
| Jugal Kishore Baid | Founder & Non Executive Director | 2M | male |
| Pankaj Kumar Gupta | President of R&D & Additional Executive Director | — | male |
| Rahul Gautam | President of Strategy & Corporate Development | — | male |
| Naresh Vijayvergiya | Chief Financial Officer | — | male |
| K. Rastogi | Assistant Vice President of Finance & Accounts | — | male |
| Lokender Kumar | Senior General Manager & HR | — | male |
| Avinash Chandra | Company Secretary & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for POLYMED.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
